Myomo® Announces New Sales and Service Agreement for Italy
March 18 2019 - 8:00AM
Business Wire
Progettiamo Autonomia Robotics Expands its
Portfolio with MyoPro®
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, today announced that it has signed an
agreement with Progettiamo Autonomia Robotics (PAR) with the
goal of offering MyoPro in Italy. PAR is a unit of Progettiamo
Autonomia, headquartered in Reggio Emilia, Italy, with 17 offices
nationwide.
PAR’s focus is on neurological pathologies. It delivers aids and
devices for orthopedic rehabilitation, and works with clinicians to
offer patients functional recovery.
“Progettiamo Autonomia Robotics aims to become the leading
robotics company in Italy,” said Cristian Iori, Progettiamo
Autonomia Robotics CEO. “We are well known in the rehabilitation
market where our focus is innovation and we are supported with a
large commercial network of partners. Myomo offers us a great
opportunity to extend our catalog, addressing a broader range of
patients and conditions and delivering better service to
rehabilitation facilities and direct to patients.”
Paul R. Gudonis, Chairman and CEO of Myomo, said, “This
agreement with PAR enables Myomo to continue to expand our
footprint in Europe, where we are already working with orthotics
and prosthetics (O&P) practices and rehabilitation facilities
in Denmark, Germany and U.K. PAR represents exactly the kind of
innovative partner with whom we expect to build a solid global
business over time.”
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. For more information, please visit
www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's future business expectations which are subject to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not
limited to, our plans for offering our MyoPro product in Italy,
expansion of its business in Europe and beyond. These
forward-looking statements are only predictions and may differ
materially from actual results due to a variety of factors. Our
actual results could differ materially from those anticipated in
these forward looking statements for many reasons, including,
without limitation, risks related to regulatory approval and market
acceptance of our products, our ability to secure and maintain
reimbursement for our products, our ability to obtain additional
funding to sustain and grow our business, and the other risk
factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that
potentially could affect Myomo's business and financial results is
included in Myomo's filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only
as of the date made. The Company disclaims any obligation
subsequently to revise any forward-looking statements to reflect
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190318005009/en/
Investor Relations:Vivian CervantesPCG
Advisory646-863-6274vivian@pcgadvisory.comPublic
Relations:Sarah KarrMatter
Communications978-518-4817myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024